{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:11:32Z","timestamp":1785816692230,"version":"3.56.0"},"reference-count":14,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2021,2,15]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Blinatumomab is a CD19 BiTE (bispecific T\u2010cell engager) immuno\u2010oncology therapy that mediates the lysis of cells expressing CD19.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A pooled analysis of long\u2010term follow\u2010up data from 2 phase 2 studies that evaluated blinatumomab in heavily pretreated adults with Philadelphia chromosome\u2013negative, relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 259 patients were included in the analysis. The median overall survival (OS) among all patients, regardless of response, was 7.5 months (95% confidence interval [CI], 5.5\u20108.5 months); the median follow\u2010up time for OS was 36.0 months (range, 0.3\u201060.8 months). The median relapse\u2010free survival (RFS) among patients who achieved a complete remission (CR) or complete remission with partial hematologic recovery (CRh) in the first 2 cycles (n = 123) was 7.7 months (95% CI, 6.2\u201010.0 months); the median follow\u2010up time for RFS was 35.0 months (range, 9.5\u201059.5 months). OS and RFS plateaued with 3\u2010year rates of 17.7% and 23.4%, respectively. The cumulative incidence function of the time to relapse, with death not due to relapse considered a competing risk, for patients who achieved a CR\/CRh within 2 cycles of treatment also plateaued with a 3\u2010year relapse rate of 59.3%. For patients who achieved a CR\/CRh with blinatumomab followed by allogeneic hematopoietic stem cell transplantation while in continuous CR, the median OS was 18.1 months (95% CI, 10.3\u201030.0 months) with a 3\u2010year survival rate of 37.2%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>These data suggest that long\u2010term survival is possible after blinatumomab therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Lay Summary<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n\n<jats:list-item><jats:p>Immuno\u2010oncology therapies such as blinatumomab activate the patient's own immune system to kill cancer cells.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>This study combined follow\u2010up data from 2 blinatumomab\u2010related clinical trials to evaluate long\u2010term survival in patients with relapsed and\/or refractory B\u2010cell precursor acute lymphoblastic leukemia at high risk for unfavorable outcomes.<\/jats:p><\/jats:list-item>\n\n<jats:list-item><jats:p>Among patients who achieved a deep response with blinatumomab, one\u2010third lived 3 years or longer. These findings suggest that long\u2010term survival is possible after treatment with blinatumomab.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.33298","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T13:32:57Z","timestamp":1604410377000},"page":"554-559","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Long\u2010term survival of patients with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab"],"prefix":"10.1002","volume":"127","author":[{"given":"Max S.","family":"Topp","sequence":"first","affiliation":[{"name":"Universit\u00e4tsklinikum W\u00fcrzburg W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"G\u00f6kbuget","sequence":"additional","affiliation":[{"name":"Goethe University Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Zugmaier","sequence":"additional","affiliation":[{"name":"Amgen GmbH Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony S.","family":"Stein","sequence":"additional","affiliation":[{"name":"Gehr Family Center for Leukemia Research, City of Hope Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"Saint Louis Hospital University of Paris Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Chen","sequence":"additional","affiliation":[{"name":"Amgen, Inc Thousand Oaks California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1042-6024","authenticated-orcid":false,"given":"Josep\u2010Maria","family":"Ribera","sequence":"additional","affiliation":[{"name":"Catalan Institute of Oncology\u2013Germans Trias I Pujol Hospital, Josep Carreras Leukemia Research Institute Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf C.","family":"Bargou","sequence":"additional","affiliation":[{"name":"Comprehensive Cancer Center Mainfranken University Hospital W\u00fcrzburg W\u00fcrzburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz\u2010August","family":"Horst","sequence":"additional","affiliation":[{"name":"University Hospital of Schleswig\u2010Holstein Kiel Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404824"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32335"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71170-2"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-06-649111"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.84"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01099-x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.0580"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32116"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.014274"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33298","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.33298","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.33298","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:17:06Z","timestamp":1760278626000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.33298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,2,15]]}},"alternative-id":["10.1002\/cncr.33298"],"URL":"https:\/\/doi.org\/10.1002\/cncr.33298","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"assertion":[{"value":"2020-07-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}